[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609809":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":33,"responsibleParty":107,"collaborators":11,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":11,"eligibilityCriteria":115,"healthyVolunteers":111,"sex":116,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":11,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":133,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"Rapport Therapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"RAP-219","EXPERIMENTAL",null,[13],"Drug: RAP-219",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.",[9],[20],{"name":21,"affiliation":22,"role":23},"Imran Quraishi, MD","Yale University","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Daniela Moreno","CONTACT","(857) 323-9048","dmoreno@rapportrx.com",{"name":31,"role":27,"phone":28,"phoneExt":11,"email":32},"Beth Bowers","bbowers@rapportrx.com",[34,48,58,67,77,87,97],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":11},"Consultants in Epilepsy and Neurology, PLLC","RECRUITING","Boise","Idaho","83702","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-116.20345,43.6135,{"lat":46,"lon":45},{"facility":49,"status":36,"city":50,"state":51,"zip":52,"country":40,"countryCode":41,"cosmosGeoPoint":53,"geoPoint":57,"contacts":11},"Mayo Clinic","Rochester","Minnesota","55905",{"type":43,"coordinates":54},[55,56],-92.4699,44.02163,{"lat":56,"lon":55},{"facility":59,"status":36,"city":60,"state":60,"zip":61,"country":40,"countryCode":41,"cosmosGeoPoint":62,"geoPoint":66,"contacts":11},"NYU Langone Comprehensive Epilepsy Center","New York","10016",{"type":43,"coordinates":63},[64,65],-74.00597,40.71427,{"lat":65,"lon":64},{"facility":68,"status":36,"city":69,"state":70,"zip":71,"country":40,"countryCode":41,"cosmosGeoPoint":72,"geoPoint":76,"contacts":11},"Cleveland Clinic Foundation","Cleveland","Ohio","44195",{"type":43,"coordinates":73},[74,75],-81.69541,41.4995,{"lat":75,"lon":74},{"facility":78,"status":36,"city":79,"state":80,"zip":81,"country":40,"countryCode":41,"cosmosGeoPoint":82,"geoPoint":86,"contacts":11},"University of Pennsylvania - Department of Neurology","Philadelphia","Pennsylvania","19104",{"type":43,"coordinates":83},[84,85],-75.16362,39.95238,{"lat":85,"lon":84},{"facility":88,"status":36,"city":89,"state":90,"zip":91,"country":40,"countryCode":41,"cosmosGeoPoint":92,"geoPoint":96,"contacts":11},"Vanderbilt University Medical Center","Nashville","Tennessee","37232",{"type":43,"coordinates":93},[94,95],-86.78444,36.16589,{"lat":95,"lon":94},{"facility":98,"status":36,"city":99,"state":100,"zip":101,"country":40,"countryCode":41,"cosmosGeoPoint":102,"geoPoint":106,"contacts":11},"Baylor College of Medicine","Houston","Texas","770300",{"type":43,"coordinates":103},[104,105],-95.36327,29.76328,{"lat":105,"lon":104},{"type":108,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100609809","phase-2-a-long-term-study-of-the-safety-and-effectiveness-of-rap-219-in-adults-with-focal-onset-seizures-100609809",false,"NCT07219407","A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures","An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures","Inclusion Criteria:\n\n* Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.\n* Diagnosis of refractory focal epilepsy\n* Stable RNS(c) system settings\n* A demonstrated history of compliance with RNS(c) system data interrogation and upload\n* Good overall health other than focal epilepsy, per Investigator.\n* BMI ≥ 18 kg\u002Fm\\^2 and ≤ 45 kg\u002Fm\\^2\n* Willing and able to adhere to all aspects of the protocol.\n\nExclusion Criteria:\n\n* Known of hypersensitivity to RAP-219\n* Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator\n* Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods","ALL","18 Years","70 Years",{"count":120,"type":121},30,"ESTIMATED","INTERVENTIONAL",[124],"PHASE2","This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.",[127,128,129,130,131,132],"Focal Epilepsy","Epilepsy","Refractory Focal Epilepsy","Seizure","Focal Seizure","Focal Onset Seizure",[134,128,135,136],"Focal Seizures","RNS","Long episode","2026-01-22",{"date":139,"type":140},"2026-01-23","ACTUAL",{"date":142,"type":140},"2025-12-15",{"date":144,"type":121},"2028-02-03",{"name":5,"class":6},7]